Patents Examined by Alma Pipic
  • Patent number: 11760823
    Abstract: The invention relates in general to hydrophilic, biocompatible dendronised polymers, to complexes comprising the dendronised polymers, to methods of preparing the dendronised polymer and to uses of the dendronised polymer as a non-viral transfection agent for the delivery of biomolecules, in particular, genome editing tools, into a cell.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: September 19, 2023
    Assignee: The University of Western Australia
    Inventors: Killugudi Swaminatha Iyer, Marck Norret, Jessica Kretzmann, Diwei Ho
  • Patent number: 11752235
    Abstract: Wound dressing compositions comprising of a bioresorbable sponge encapsulated within a polysaccharide envelope. The bioresorbable sponge is preferably comprised of collagen and oxidised regenerated cellulose. The outer polysaccharide envelope is preferably comprised of chitosan. The outer polysaccharide envelope functions to modulate the rate at which the bioresorbable sponge breaks down within a wound.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: September 12, 2023
    Assignee: KCI Licensing, Inc.
    Inventors: Craig Delury, Alexander Waite
  • Patent number: 11752077
    Abstract: This oily moisturizer is composed of either an esterified product of a component A that is ditrimethylolpropane, and a component B that is one fatty acid, or two or more fatty acids, selected from among saturated fatty acids of 6 to 12 carbon atoms, or an esterified product of the component A, the component B, and a component C that is one fatty acid, or two or more fatty acids, selected from among fatty acids of 13 to 28 carbon atoms, wherein the hydroxyl value of the esterified product is not more than 140 mgKOH/g, and the mass ratio between fatty acid residues derived from the component B and fatty acid residues derived from the component C within the fatty acid residues that constitute the esterified product of the component A, the component B and the component C is within a range from 99.9:0.1 to 60:40.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: September 12, 2023
    Assignee: THE NISSHIN OILLIO GROUP, LTD.
    Inventors: Hirofumi Denda, Tadashiro Hirose, Hisanori Kachi
  • Patent number: 11744748
    Abstract: The present disclosure relates to absorbent garments having a dryness layer that can comprise one or more laminates and one or more channels to facilitate liquid acquisition and retention. Laminate(s) can include an absorbent lamina disposed between substrate laminae, each comprising tissue and/or a nonwoven. Some dryness layers can have a folded laminate that defines a longitudinally-extending channel. Some dryness layers can have two or more laminate strips that are laterally spaced apart along a width of the dryness layer such that one or more longitudinally-extending channels are defined therebetween.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: September 5, 2023
    Assignee: ATTENDS HEALTHCARE PRODUCTS, INC.
    Inventors: Harry Chmielewski, Michael Kalmon, Matthew Ashcraft, Paul Ducker
  • Patent number: 11738091
    Abstract: A combination therapy involving different therapeutic molecules can enhance and improve the therapeutic potentials. An effective therapeutic strategy conjugates silica (SiO2) nanoparticles with, e.g., 3-glycidyloxypropyl, trimethoxysilane and azoles, e.g., 1,2,4-triazole (Tri), 3-aminotriazole (ATri), 5-aminetetrazole (Atet), imidazole (Imi). These exemplary materials—classified as SiO2-3GPS-Tri (Conj. 1), SiO2-3GPS-Atri (Conj. 2), SiO2-3GPS-Atet (Conj. 3), SiO2-3GPS-Btri (Conj. 4), and SiO2-3GPS-Imi (Conj. 5)—can amplify targeting of therepeutics for human colorectal carcinoma cells (HCT-116), enhancing anti-cancer effects.
    Type: Grant
    Filed: November 17, 2022
    Date of Patent: August 29, 2023
    Assignee: Imam Abdulrahman Bin Faisal University
    Inventors: Sarah Mousa Asiri, Firdos Alam Khan, Ayhan Bozkurt
  • Patent number: 11738113
    Abstract: Gamma ray and e-beam irradiation provided efficient sterilization of certain self-assembling peptides (including RADA16 in solution) without substantial degradation of the major peptide, while, e.g., another self-assembly peptide, QLEL12 was significantly degraded following irradiation. Irradiation sterilization enhances the rheological property of, for example, RADA16 hydrogel once applied to tissue at a physiological pH. The rheological property increase can result in higher efficacy in a variety of biomedical applications.
    Type: Grant
    Filed: November 6, 2022
    Date of Patent: August 29, 2023
    Assignee: 3-D Matrix, Ltd.
    Inventors: Marika G. Rioult, Eun Seok Gil, Elton Aleksi, Naoki Yamamoto
  • Patent number: 11738114
    Abstract: Gamma ray and e-beam irradiation provided efficient sterilization of certain self-assembling peptides (including RADA16 in solution) without substantial degradation of the major peptide, while, e.g., another self-assembly peptide, QLEL12 was significantly degraded following irradiation. Irradiation sterilization enhances the rheological property of, for example, RADA16 hydrogel once applied to tissue at a physiological pH. The rheological property increase can result in higher efficacy in a variety of biomedical applications.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: August 29, 2023
    Assignee: 3-D Matrix, Ltd.
    Inventors: Marika G. Rioult, Eun Seok Gil, Elton Aleksi, Naoki Yamamoto
  • Patent number: 11732139
    Abstract: There is provided a method for decreasing leakage of matter from an object to a surrounding, said object being coated with a coating at least partially applied on the object, said coating comprising an at least partially covering layer comprising silver, said object optionally comprising area(s) without said layer, said coating comprising metal particles applied on the layer and optionally on areas without said layer, said metal particles comprising palladium and at least one metal selected from the group consisting of gold, ruthenium, rhodium, osmium, iridium, niobium, neodymium and platinum and wherein the amount of the metal particles is in the interval 0.01-8 ?g/cm2. Advantages include that leakage of matter such as latex allergens of metal ions can be reduced while the coating is both biocompatible and antimicrobial. Further, the blood clotting can be reduced.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: August 22, 2023
    Assignee: BACTIGUARD AB
    Inventors: Billy Södervall, Javier Sanchez
  • Patent number: 11730479
    Abstract: The present invention is directed to a nerve regeneration conduit including a resorbable tube having a matrix therein. The matrix is characterized by substantially parallel, axially aligned pores extending the length of the matrix. The matrix is formed by the axial freezing of a slurry having little or no significant radial thermal gradient during the freezing process. The matrix is used to bridge the gap between the severed ends of a nerve and provide a scaffold for nerve regeneration.
    Type: Grant
    Filed: November 8, 2021
    Date of Patent: August 22, 2023
    Assignee: Integra LifeSciences Corporation
    Inventors: Simon J. Archibald, Fergal O'Brien, Amos Matsiko
  • Patent number: 11723363
    Abstract: Techniques regarding polymers with antimicrobial functionality are provided. For example, one or more embodiments described herein can regard a polymer, which can comprise a repeating ionene unit. The repeating ionene unit can comprise a cation distributed along a degradable backbone. The degradable backbone can comprise a terephthalamide structure. Further, the repeating ionene unit can have antimicrobial functionality.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: August 15, 2023
    Assignees: INTERNATIONAL BUSINESS MACHINES CORPORATION, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Mareva B. Fevre, James L. Hedrick, Nathaniel H. Park, Victoria A. Piunova, Pang Kern Jeremy Tan, Chuan Yang, Yi Yan Yang
  • Patent number: 11701335
    Abstract: Methods of normalizing amino acid metabolism in subjects on restricted protein diets and supplemental amino acids, using specially formulated amino acids that mimic the absorption and metabolism of naturally occurring proteins, are described.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: July 18, 2023
    Assignee: APR Applied Pharma Research s.a.
    Inventors: Alberto Reiner, Giorgio Reiner
  • Patent number: 11701325
    Abstract: A stable liquid formulation is provided. The liquid formulation includes a composition of active ingredients paeonol and apocynin. Methods of production of such a formation and treatment of diseases administering such a formulation are also provided.
    Type: Grant
    Filed: November 22, 2018
    Date of Patent: July 18, 2023
    Assignee: AKL RESEARCH & DEVELOPMENT LTD
    Inventor: Nicholas John Larkins
  • Patent number: 11696885
    Abstract: The invention relates to a dispersion containing at least one rhamnolipid derivative and also to the use of the rhamnolipid derivatives as emulsifier or dispersing aid.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: July 11, 2023
    Assignee: Evonik Operations GmbH
    Inventors: Xin Lu, Sandra Nattland, Achim Friedrich, Hans Henning Wenk
  • Patent number: 11672822
    Abstract: Methods and compositions are provided for preventing and/or treating infection by disrupting interactions at or near the surface of mannosylated pathogens or other pathogens exhibiting carbohydrate-carbohydrate self-interaction, thus enhancing the immune system's ability to recognize and destroy such pathogens. In some forms, carrier molecules are provided to delivering polymers or other molecules capable of disrupting intra-cellular interaction and/or self-interaction of surface markers on cells.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: June 13, 2023
    Assignee: HOWARD UNIVERSITY
    Inventor: Preethi Chandran
  • Patent number: 11666682
    Abstract: A method and kit for stopping cerebrospinal fluid (CSF) leaks, comprising penetrating and passing through a dural tissue an applicator to access an interior dural space, injecting from the applicator a fibrinogen-containing solution into said dural space, applying a sealing member containing a fibrinogen polymerizing agent onto an exterior surface of the dural tissue, and forming a polymerized fibrinogen or polymerized fibrin clot by contacting the injected fibrinogen-containing solution and the fibrinogen polymerizing agent.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: June 6, 2023
    Assignee: Ethicon, Inc.
    Inventors: Ashley Deanglis, Salim Ghodbane, Kevin Shaun Weadock
  • Patent number: 11660349
    Abstract: Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: May 30, 2023
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jie Fu, Peter A. Campochiaro, Justin Scot Hanes
  • Patent number: 11643509
    Abstract: The invention relates to a hydrogel product comprising glycosaminoglycan molecules as the swellable polymer, wherein the glycosaminoglycan molecules are covalently crosslinked via crosslinks comprising a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: May 9, 2023
    Assignee: Galderma Holding SA
    Inventors: Hotan Mojarradi, Johan Olsson, Craig Steven Harris, Jean-Guy Boiteau, Thibaut Gerfaud, Loïc Tomas
  • Patent number: 11617367
    Abstract: Techniques regarding chemical compounds with antimicrobial functionality are provided. For example, one or more embodiments describe herein can comprise a monomer that can comprise a molecular backbone. The molecular backbone can comprise a bis(urea)guanidinium structure covalently bonded to a functional group, which can comprise a radical. Also, the monomer can have supramolecular assembly functionality.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: April 4, 2023
    Assignees: INTERNATIONAL BUSINESS MACHINES CORPORATION, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: James L. Hedrick, Mareva B. Fevre, Nathaniel H. Park, Victoria A. Piunova, Yi Yan Yang, Pang Kern Jeremy Tan
  • Patent number: 11617712
    Abstract: The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the pharmaceutical compositions comprise at least one pharmaceutically active ingredient, at least one non-cellulose polysaccharide, at least one hydrophilic gelling polymer, and an effervescent system.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: April 4, 2023
    Assignee: SpecGX LLC
    Inventors: Alex Micka, Kai Feng, Tsz Chung Lai, Jonathan Gaik
  • Patent number: 11607394
    Abstract: The present invention provides a rotigotine-containing patch comprising: a backing layer; and an adhesive agent layer, wherein the adhesive agent layer contains rotigotine and/or a pharmaceutically acceptable salt thereof, the adhesive agent layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and/or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinylpyrrolidone, and in the adhesive agent layer, a mass ratio of a content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form and a content of the cross-linked polyvinylpyrrolidone (content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form:content of the cross-linked polyvinylpyrrolidone) is 10:3 to 1:3.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: March 21, 2023
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Hiroyuki Araki, Yuka Takagi, Yoko Fujiwara, Hiroaki Kobayashi, Takao Kurokawa